GLPwatch
Papers (10386)
Page 136 of 174, ranked by citation count.
- The anorexic effect of Ex4/Fc through GLP-1 receptor activation in high-fat diet fed mice.
- Fabrication and Preclinical Evaluation of Hyaluronic Acid/Aminoclay Nanocomposite Microneedles for Noninvasive Delivery of Semaglutide in Anti-Obesity Therapy.
- Multi-pathway-driven hepatic protection: Semaglutide combined with HIIT counteracts diabetic liver injury in db/db mice.
- A Descriptive Analysis from VigiAccess on Drug-related Problems Associated with the Glucagon-like Peptide-1 Receptor Agonists.
- GLP-1 receptor agonist liraglutide facilitates rotator cuff healing by reducing tendon cell inflammation and endoplasmic reticulum stress through the GLP-1R-AMPK/SIRT1 pathway.
- Saving muscle while losing weight: A vital strategy for sustainable results while on glucagon-like peptide-1 related drugs.
- Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China.
- An Increase of Heart Rate and Electrocardiographic Changes after Subcutaneous Liraglutide.
- The Impact of Liraglutide, a GLP-1 Receptor Agonist, on High Glucose-Induced Inflammation, Apoptosis, Oxidative Stress, and NLRP3 Signaling.
- Irisin and liraglutide combination therapy mitigates myocardial reperfusion injury in obese rats: Role of endoplasmic reticulum stress and apoptosis.
- Glucagon-like peptide-1 receptor agonists reduce experimental atherosclerosis progression, inflammatory biomarkers and cardiovascular events, irrespective of hyperglycaemia and obesity.
- Real-world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network.
- Treatment persistence, adherence and healthcare resource utilisation for iGlarLixi versus basal-bolus insulin or premixed insulin in older adult ethnic minorities with type 2 diabetes: SoliEthnicity study.
- Molecular Mechanisms of Liraglutide Aggregation Induced by Dual Air-Water and Silicone-Oil-Water Interfacial Stress.
- Multivalent γ-PGA-Exendin-4 Conjugates to Target Pancreatic β-Cells.
- DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.
- Ozempic keeps wowing: trial data show benefits for kidney disease.
- [Tirzepatide : overview of clinical studies SURPASS in type 2 diabetes and SURMOUNT in obesity].
- What the SELECT trial of semaglutide means for clinicians.
- Utilization of antiobesity medications within the Military Health System.
- Long-term efficacy of daily oral semaglutide as add-on or switch therapy in adults with type 2 diabetes: a 12-month real-world retrospective study.
- Growth differentiation factor 15 is not modified after weight loss induced by liraglutide in South Asians and Europids with type 2 diabetes mellitus.
- Chronotropic Responses to GLP-1 Receptor Agonists and Sitagliptin in Atria From Diabetic Rats.
- Effect of Exenatide Therapy on Platelet Function in Type 2 Diabetes Mellitus.
- Rational design and evaluation of GLP-1 derivative for treating hyperglycemia combined with overexercise-induced myocardial injury.
- In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk.
- Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.
- Accuracy of dosage volume for halfway doses in the Victoza Pen.
- Integrating Drug Target Information in Deep Learning Models to Predict the Risk of Adverse Events in Patients with Comorbid Post-Traumatic Stress Disorder and Alcohol Use Disorder.
- Possible dulaglutide-associated cholecystitis with safe continuation post cholecystectomy.
- Acute Kidney Injury After Accelerated Dosing of Tirzepatide in a Patient with Multiple Comorbidities: A Case Report.
- Structural stability-chromatographic retention relationship on exenatide diastereomer separation.
- Durability of Glucose-Lowering Effect of the First Administration of Dulaglutide: A Retrospective, Single-Center, Single-Arm Study.
- Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis.
- Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes.
- Taking back control: The experience of adults using semaglutide and tirzepatide for obesity treatment - A qualitative study.
- Unlocking the potential of microfluidic assisted formulation of exenatide-loaded solid lipid nanoparticles.
- Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials.
- Sustained Islet Allograft Function After Peritransplant Treatment Using Exenatide With and Without Everolimus.
- Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed-ratio basal insulin glucagon-like peptide-1 receptor agonist combinations?
- Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920.
- GLP-1 receptor agonist exenatide uncouples food intake from hedonic and anticipatory regulation in non-human primates: insights from an operant meal schedule paradigm.
- In brief: New FDA warning of pulmonary aspiration with GLP-1 receptor agonists.
- Hot Water Eliminates the Bitter Taste of Oral Semaglutide: A Report of Four Cases.
- Therapy for HFpEF: A step forward brings new hope for people with obesity and diabetes.
- Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER-2 trial emulation with real-world data.
- Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers.
- Effects of dulaglutide combined with insulin degludec on glucose fluctuations and appetite in type 2 diabetes.
- Pharmacological Signatures of the Exenatide Nanoparticles Against Hepatic Ischemia/Reperfusion-induced Pancreatic Injury.
- Convergent Metabolic Pathways in MASH Therapeutics: An AMPK-Centric Analysis.
- Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.
- Therapeutic effect of liraglutide on expression of CTGF and BMP-7 in induced diabetic nephropathy.
- iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents.
- The effect of human serum albumin glycation on the binding of antidiabetic agent-exenatide; the multispectroscopic studies. Part II.
- Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety.
- Efficacy and safety of orforglipron in type 2 diabetes mellitus and obesity: a GRADE-assessed meta-analysis and trial sequential analysis with subgroup evaluations by diabetic status, obesity status, and dose regimens.
- Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
- [Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials].
- Insulin requirements after switching from GLP-1 receptor agonist to dual GIP/GLP-1 receptor agonist in patients with type 2 diabetes mellitus.
- Cancer prevention and interception with antidiabetic and anti-obesity drugs: Current and future perspectives.